Board

Board of directors

Board of directors

Chairman, Ph.D.

Johan Häggblad

Johan Häggblad has more than 30 years of experience in the pharmaceutical industry in managerial and executive roles. Johan is Chief Scientific Officer at Calliditas. Prior to that, he served as CEO of Pharmalink between 2007 and 2017. His previous management positions were at NeuroNova, Pharmacia Corporation, and Karo Bio AB. Johan has a PhD in neurochemistry and neurotoxicology from Stockholm University and did his postdoc in pharmacology and physiology at New York University and the University of Oxford.

Board member since 2022.

Holdings in AroCell: Nil shares.

Independent in relation to the company and its management and in relation to major shareholders.

Ph.D.

Eva Nordström

Eva has a Ph.D. in immunology under Prof. Erna Möller at Stockholm University and is currently working as a Senior Researcher at BioArctic AB. She has wide scientific experience from assay development, hybridoma generation and immunoassays.

Board member since 2020

Holdings in AroCell: 72 470 shares.

Independent in relation to the company and its management and in relation to major shareholders.

Ph.D.

Charlotta Ljungqvist

Charlotta Ljungqvist is also a board member of NorthXBiologics, BioLamina, BioArctic AB, Genovis Aktiebolag, Atlas Antibodies AB, SwedenBio Service AB and 4L Bioconsulting AB. Previously, she was head of R&D BioProcess GE Life Sciences at GE Healthcare. She has a Ph.D. in biochemistry from the Royal Institute of Technology in Stockholm. In 2007/2008, she was the CEO of IMEA AB, a biotechnology company that develops biological drugs. Prior to that, Charlotta Ljungqvist was responsible for the Biopharmaceutical Contract Manufacturing Organization within Biovitrum during the years 2001–2007. 

Board member since 2021

Holdings in AroCell: Nil shares

Independent in relation to the company and its management and in relation to major shareholders.

    M.B.A.

    Max Pihlqvist

    Max Pihlqvist has a master’s degree in business administration from Lund University and significant experience in the laboratory and diagnostics industry. Max Pihlqvist has previous experience from IDL Biotech as a board member during the years 2017-2019.

    Today, Max works as Deputy CEO of the Svenska Labex AB Group with subsidiaries in Norway and Denmark and is Chairman of the Board of Labbex forvaltnings AB, Norsk Labex AS, Labex APS and Labex Reagens AB.

    Board member since 2022

    Holdings in AroCell: Nil shares

    Is dependent in relation to one of the company’s major owners.

      B.S.Chem.

      Agneta Tufvesson Alm

      Agneta Tufvesson Alm has more than 30 years of experience in international sales and marketing as well as experience in direct sales in the Nordic countries and the United Kingdom, region and key account management in Europe, Africa, and the Middle East. Agneta has worked with building distribution networks, contract negotiations, and management of sales and customer service teams. She currently works at Kemira Kemi AB and has previously held roles at HemoCue AB, Thermo Quest, and Kabi Pharmacia. Agneta has a bachelor’s degree in chemistry from Lund University.

      Board member since 2022

      Holdings in AroCell: Nil shares

      Independent in relation to the company and its management and in relation to major shareholders.

        About us

        We provide knowledge to decision.

        AroCell is a Swedish diagnostics company with the vision to improve the monitoring of oncological and bacterial diseases. We have a broad product portfolio of IVD tests that deliver high-value clinical information for the detection of diseases.

        Bacteriology

        An effective typhoid test

        Typhoid fever is water and food-borne infectious disease caused by the bacterium, Salmonella enterica. IDL Biotechs product TUBEX® TF, is a rapid and sensitive in vitro diagnostic test for the detection of acute typhoid fever.

        Oncology

        Diagnostics for oncology

        Cancer is one of the leading causes of death worldwide, despite advancing knowledge. To improve cancer patient management, there is a clear need for efficient diagnostics tools to capture this critical clinical data.